JP6275137B2 - 治療薬分与デバイスおよびその作製方法 - Google Patents

治療薬分与デバイスおよびその作製方法 Download PDF

Info

Publication number
JP6275137B2
JP6275137B2 JP2015526643A JP2015526643A JP6275137B2 JP 6275137 B2 JP6275137 B2 JP 6275137B2 JP 2015526643 A JP2015526643 A JP 2015526643A JP 2015526643 A JP2015526643 A JP 2015526643A JP 6275137 B2 JP6275137 B2 JP 6275137B2
Authority
JP
Japan
Prior art keywords
drug
eye
corneal
nanowafer
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015526643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524473A5 (enExample
JP2015524473A (ja
Inventor
ガナシャム アチャリヤ，
ガナシャム アチャリヤ，
スティーブン シー． フルーグフェルダー，
スティーブン シー． フルーグフェルダー，
パイバ， シンティア エス． デ
パイバ， シンティア エス． デ
ジェニファー エル． シンプソン，
ジェニファー エル． シンプソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2015524473A publication Critical patent/JP2015524473A/ja
Publication of JP2015524473A5 publication Critical patent/JP2015524473A5/ja
Application granted granted Critical
Publication of JP6275137B2 publication Critical patent/JP6275137B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/005—Templates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A61F2310/00383—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C33/00—Moulds or cores; Details thereof or accessories therefor
    • B29C33/38—Moulds or cores; Details thereof or accessories therefor characterised by the material or the manufacturing process
    • B29C33/3842—Manufacturing moulds, e.g. shaping the mould surface by machining
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C39/00—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor
    • B29C39/02—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/712—Containers; Packaging elements or accessories, Packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015526643A 2012-08-06 2013-08-06 治療薬分与デバイスおよびその作製方法 Expired - Fee Related JP6275137B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261679908P 2012-08-06 2012-08-06
US61/679,908 2012-08-06
US201361775891P 2013-03-11 2013-03-11
US61/775,891 2013-03-11
PCT/US2013/053805 WO2014025792A1 (en) 2012-08-06 2013-08-06 Therapeutics dispensing device and methods of making same

Publications (3)

Publication Number Publication Date
JP2015524473A JP2015524473A (ja) 2015-08-24
JP2015524473A5 JP2015524473A5 (enExample) 2016-08-18
JP6275137B2 true JP6275137B2 (ja) 2018-02-07

Family

ID=50068523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015526643A Expired - Fee Related JP6275137B2 (ja) 2012-08-06 2013-08-06 治療薬分与デバイスおよびその作製方法

Country Status (6)

Country Link
US (2) US10251778B2 (enExample)
EP (1) EP2879761A4 (enExample)
JP (1) JP6275137B2 (enExample)
AU (1) AU2013299785B2 (enExample)
CA (1) CA2881010A1 (enExample)
WO (1) WO2014025792A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
AU2014236455B2 (en) * 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN107430118A (zh) * 2013-06-27 2017-12-01 广东盛泽康华生物医药有限公司 对自身免疫状况的分类与管理的方法与仪器
US10613356B2 (en) * 2013-09-09 2020-04-07 The General Hospital Corporation Remotely controllable lens device
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
WO2015117702A1 (en) 2014-02-10 2015-08-13 Philip Morris Products S.A. An aerosol-generating system having a fluid-permeable heater assembly
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
MX2019004555A (es) 2016-10-19 2019-08-05 Swimc Llc Aditivos de resinas solubles en alcali y composiciones del revestimiento que incluyen tales aditivos.
US11484516B2 (en) 2017-03-29 2022-11-01 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
WO2019060704A1 (en) * 2017-09-22 2019-03-28 University Of Florida Research Foundation DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
BR112021013455A2 (pt) * 2019-01-09 2021-09-14 Twenty Twenty Therapeutics Llc Dispositivo de dispensação de agente terapêutico, e, sistema
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US20220054714A1 (en) * 2019-01-15 2022-02-24 University Of Utah Research Foundation Drug-delivering nerve wrap
US20220265695A1 (en) 2019-07-26 2022-08-25 Proqr Therapeutics Ii B.V. Opthalmic compositions comprising viscosifying polymers and nucleic acids
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
US20210378993A1 (en) * 2020-06-08 2021-12-09 Nacuity Pharmaceuticals, Inc. Treatment of cystinosis
EP3922282A1 (en) * 2020-06-09 2021-12-15 Dompe' Farmaceutici S.P.A. New drug delivery system for ophtalmic use
WO2022101911A1 (en) * 2020-11-11 2022-05-19 Hadasit Medical Research Services And Development Ltd. Bioadhesive film and methods of use thereof
EP4312917A1 (en) * 2021-03-24 2024-02-07 Ocular Therapeutix, Inc. Implant injector device
IT202200008621A1 (it) * 2022-04-29 2023-10-29 Sifi Spa Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788957A (en) * 1991-10-15 1998-08-04 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
US7070590B1 (en) * 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
EP1226465B1 (en) * 1999-11-01 2006-01-11 Praful Doshi Tinted polymer contact lens and method of manufacturing the same
EP1372602B1 (en) 2001-01-09 2007-04-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US20080132444A1 (en) 2004-10-09 2008-06-05 Xiaoling Li Ocular Agent Delivery Systems
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US7878650B2 (en) * 2006-06-29 2011-02-01 Fritsch Michael H Contact lens materials, designs, substances, and methods
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009042231A2 (en) 2007-09-27 2009-04-02 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
EP2396070B1 (en) * 2009-02-12 2024-12-04 Incept Llc Drug delivery through hydrogel plugs
EP2427179A4 (en) * 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
US20120130300A1 (en) 2009-07-14 2012-05-24 Board Of Regents, The Univerity Of Texas System Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics
EP2600920A4 (en) 2010-08-05 2017-10-04 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery

Also Published As

Publication number Publication date
EP2879761A4 (en) 2016-03-02
JP2015524473A (ja) 2015-08-24
US10251778B2 (en) 2019-04-09
AU2013299785B2 (en) 2017-09-07
US20190282398A1 (en) 2019-09-19
AU2013299785A1 (en) 2015-02-19
CA2881010A1 (en) 2014-02-13
WO2014025792A1 (en) 2014-02-13
EP2879761A1 (en) 2015-06-10
US20150190279A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
JP6275137B2 (ja) 治療薬分与デバイスおよびその作製方法
Lanier et al. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations
Kwon et al. Potential therapeutic usage of nanomedicine for glaucoma treatment
Gan et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers
Achouri et al. Recent advances in ocular drug delivery
EP3233056B1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
Calles et al. Polymers in ophthalmology
Ratay et al. Modern therapeutic approaches for noninfectious ocular diseases involving inflammation
Sah et al. Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate
Billowria et al. Topical advances in mucoadhesive ocular drug delivery system
Sharma et al. A Mini-review on New Developments in nanocarriers and polymers for ophthalmic drug delivery strategies
Wang et al. Injectable drug-loaded thermosensitive hydrogel delivery system for protecting retina ganglion cells in traumatic optic neuropathy
So et al. Emerging trends in long-acting sustained drug delivery for glaucoma management
Das et al. Drug delivery to eye: Special reference to nanoparticles
HS Boddu Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity
US20200206137A1 (en) Microparticle formulations for delivery of active agents
Khokhar et al. Ocular drug Delivery system-a review based on ocuserts
Tejpal et al. Microspheres as an ocular drug delivery system–a review
Khan et al. Ocular Drug Delivery: Introduction and Fundamental Concept
Zafar et al. Nanotechnology for transcorneal drug targeting in glaucoma: challenges and progress
Nair et al. Current trends in ocular drug delivery systems and its applications
Mustafa Ophthalmology: Navigating ocular barriers with advanced nanocarriers
Chang Recent advances in ophthalmic drug delivery
Chen et al. Medical Treatment Strategy for Glaucoma
Dwivedi et al. Review on ocular inserts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180109

R150 Certificate of patent or registration of utility model

Ref document number: 6275137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees